Komatsu Hiroyuki, Fujimoto Shouichi, Sato Yuji, Yasuda Takashi, Yasuda Yoshinari, Matsuzaki Keiichi, Hirano Keita, Kawamura Tetsuya, Yokoo Takashi, Suzuki Yusuke, Maruyama Shoichi
Center for Medical Education and Career Development, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Department of Medical Environment Innovation, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Clin Exp Nephrol. 2024 Dec;28(12):1272-1281. doi: 10.1007/s10157-024-02530-6. Epub 2024 Jul 2.
The effects of tonsillectomy combined with steroid pulse (TSP) therapy for IgA nephropathy (IgAN) are little known. Therefore, we examined the effects of TSP therapy on the kidney outcomes of IgAN in a large, nationwide cohort study in Japan.
Between 2002 and 2004, 632 IgAN patients with ≥ 0.5 g/day proteinuria at diagnosis were divided into three groups with mild (0.50-0.99 g/day; n = 264), moderate (1.00-1.99 g/day, n = 216), or severe (≥ 2.00 g/day; n = 153). Decline in kidney function and urinary remission were compared among the three groups after TSP therapy, corticosteroid (ST) therapy, or conservative therapy during a mean follow-up of 6.2 ± 3.3 years. 10.6% and 5.9% of patients in the ST and conservative therapy group underwent tonsillectomy.
The rate of urinary remission at the final observation was significantly higher in the TSP therapy group than in the ST or conservative therapy groups (mild proteinuria: 64%, 43%, and 41%; moderate proteinuria: 51%, 45%, and 28%; severe proteinuria: 48%, 30%, and 22%, respectively). In contrast, the rate of a 50% increase in serum creatinine was lower in groups TSP therapy, than ST or conservative therapy (mild proteinuria: 2.1%, 10.1% and 16.7%; moderate proteinuria: 4.8%, 8.8% and 27.7%; severe proteinuria: 12.0%, 28.9% and 43.1%, respectively). In multivariate analysis, TSP therapy significantly prevented a 50% increase in serum creatinine levels compared with conservative therapy in groups with moderate and severe proteinuria (hazard ratio, 0.12 and 0.22, respectively).
TSP significantly increased the rate of proteinuria disappearance and urinary remission in IgAN patients with mild-to-moderate urinary protein levels. It may also reduce the decline in kidney function in patients with moderate-to-severe urinary protein levels.
扁桃体切除术联合类固醇冲击(TSP)疗法对IgA肾病(IgAN)的影响鲜为人知。因此,我们在日本一项大型全国性队列研究中,研究了TSP疗法对IgAN患者肾脏预后的影响。
2002年至2004年期间,632例确诊时蛋白尿≥0.5g/天的IgAN患者被分为三组,轻度蛋白尿组(0.50 - 0.99g/天;n = 264)、中度蛋白尿组(1.00 - 1.99g/天,n = 216)或重度蛋白尿组(≥2.00g/天;n = 153)。在平均6.2±3.3年的随访期间,比较了TSP疗法、皮质类固醇(ST)疗法或保守疗法后三组患者肾功能下降情况和尿缓解情况。ST疗法组和保守疗法组分别有10.6%和5.9%的患者接受了扁桃体切除术。
最终观察时,TSP疗法组的尿缓解率显著高于ST疗法组或保守疗法组(轻度蛋白尿:分别为64%、43%和41%;中度蛋白尿:分别为51%、45%和28%;重度蛋白尿:分别为48%、30%和22%)。相比之下,TSP疗法组血清肌酐升高50%的发生率低于ST疗法组或保守疗法组(轻度蛋白尿:分别为2.1%、10.1%和16.7%;中度蛋白尿:分别为4.8%、8.8%和27.7%;重度蛋白尿:分别为12.0%、28.9%和43.1%)。在多变量分析中,与中度和重度蛋白尿组的保守疗法相比,TSP疗法显著降低了血清肌酐水平升高50%的风险(风险比分别为0.12和0.22)。
TSP显著提高了轻度至中度尿蛋白水平的IgAN患者蛋白尿消失率和尿缓解率。它还可能降低中度至重度尿蛋白水平患者的肾功能下降。